Mitchell AP, Winn AN, Dusetzina SB. Pharmaceutical industry payments and oncologists’selection of targeted cancer therapies in Medicare beneficiaries. JAMA Intern Med 2018;178:junio. [Ref.ID 102773]

Anónimo. Inotuzumab ozogamicine et leucémie aiguë lymphoblastique chez les adultes. Prescrire 2018;38:494-9. [Ref.ID 102757]

Anónimo. Novartis, Gilead CAR-T therapies both gain European panel recommendation. DIA Daily 2018:2. [Ref.ID 102703]

Begley S, Empinado H. STAT Plus: CAR-T is a personalized attack on cancer. Here’s how it works. STAT Daily Recap 2018:6. [Ref.ID 102483]

Anónimo. FDA Approves CAR-T therapy for treatment of childhood leukemia. DIA Daily 2017:1. [Ref.ID 102036]

Al-Khateeb Z, Hadker N, Scaife JG, Miyasato G, Sanchez H. What we value: the proposition behind the price. Trinity Partners 2017:24 de mayo. [Ref.ID 101602]

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

Anónimo. Blinatumomab for acute lymphoblastic leukaemia. Australian Prescriber 2016;39:221. [Ref.ID 101023]

Anónimo. Juno suspends clinical trial after two additional patient deaths. DIA Daily 2016:4. [Ref.ID 100980]

Anónimo. UK’s NICE recommends ibrutinib after discount. DIA Daily 2016:2. [Ref.ID 100979]

Anónimo. FDA grants priority review to Novartis’ leukemia drug. DIA Daily 2016:2. [Ref.ID 100923]

Anónimo. EMA advisory committee conditionally approves venetoclax. DIA Daily 2016:3. [Ref.ID 100811]

Kantarijian HM, DeAngelo DJ, Stellijes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS. Inotuzumb ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016;375:740-53. [Ref.ID 100716]

Anónimo. Ibrutinib. Prescrire 2016;35:10-1. [Ref.ID 100521]

Anónimo. NICE endorses bosutinib for treatment of myeloid leukemia. DIA Daily 2016:3. [Ref.ID 100484]

Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker L-M, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet 2016;387:2402-11. [Ref.ID 100407]

Alpern JD, Song J, Stauffer WM. Essential medicines in the United States - Why access is diminishing. N Engl J Med 2016;374:1904-7. [Ref.ID 100324]

Anonimo. Colombia to issue compulsory license if Novartis refuses to reduce price of leukemia drug. DIA Daily 2016:1. [Ref.ID 100317]

Anónimo. Idelalisib (Zydelig): restricciones temporales de uso para prevenir infecciones graves mientras se realiza la revaluación europea del balance beneficio-riesgo . Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2016:18 de marzo. [Ref.ID 100074]

Anónimo. EMA recommends orphan drug status for acalabrutinib. DIA Daily 2016:1. [Ref.ID 100017]